Segregation in cryogenic storage means holding biological samples apart according to their regulatory status — in separate rooms, dedicated tanks or clearly defined zones, each with its own documentation. For any organisation that runs research and patient care on the same site, getting research-grade vs clinical-grade storage right is one of the most consequential decisions in its biological sample storage.
University hospitals, academic medical centres and translational institutes do both under one roof: biobanks and cell lines for research, stem cell products and cell therapies for patients. The tanks often share a building, and sometimes a room.
Pooling spare capacity is tempting. It has two consequences that cost more than any additional tank: regulatory scope creep and a genuine contamination risk.
Research-grade and clinical-grade material should not share a tank because mixing them fails in one of two directions: either the clinical product pulls the entire tank, with its documentation, access and qualification, into GMP scope, or it sits in an environment that was never qualified for material intended for human use.
Failure one: scope creep. The moment a clinical product goes into a research tank, that tank becomes part of the GMP environment. It now needs qualification, temperature mapping, calibration records, change control and a complete alarm history — and everyone who opens it needs the corresponding training.
If that does not happen, the product is stored in an unqualified environment. Any inspector will raise it as a finding, and it may call into question whether the product can still be used.
Failure two: contamination travels. Research material is frequently untested for infectious markers: primary patient material, cell lines that are not fully characterised, viral vectors. Liquid nitrogen is not sterile. A case reported in The Lancet in 1995 described hepatitis B virus being transmitted, via a contaminated liquid nitrogen tank in a transplant unit, to the stem cell harvests of other patients.
Vapour-phase storage above the liquid level reduces this risk considerably. It does not replace segregation: filling, damaged containers and ice deposits inside the tank remain potential transmission routes.
Clinical sample segregation does not stop at the boundary between research and patient care. Within the clinical inventory, quarantined material, released material and material with positive infectious-disease results each need their own clearly defined storage location.
Commission Directive 2006/17/EC, which implements the EU Tissues and Cells Directive 2004/23/EC, is explicit on this point: autologous material with positive test results may still be stored, provided appropriate isolated storage facilities rule out cross-contamination with other grafts and mix-ups. The directive is being replaced by the SoHO Regulation (EU) 2024/1938, which applies from August 2027.
In the United States, the FDA's rules for human cells and tissues (21 CFR Part 1271) likewise require storage areas to be controlled against mix-ups, contamination and cross-contamination. For haematopoietic stem cell programmes, FACT-JACIE accreditation adds the expectation of defined, documented rules for storing quarantined products and products with positive infectious-disease markers.
Research-grade and clinical-grade storage should be separated by dedicated tanks at the very least, and often by separate rooms. Zoning within a single tank is only defensible between inventories of the same quality tier. The segregation hierarchy, from strongest to weakest:
For quarantine and infectious-positive material, dedicated quarantine storage in its own tank is the robust answer. Quarantined material is by definition not yet fully tested — it can turn out positive after spending weeks next to released products.
Dedicated tanks are only as effective as the organisation behind them: an inventory system with a status field, unambiguous labelling, role-based access, per-tank monitoring, separate SOPs and documented status changes. Miss one, and the next product still ends up in the wrong vessel.
Direction matters. Material can move from clinical to research use — surplus products with appropriate consent, for instance. The reverse route is, as a rule, closed.
Consistent segregation confines GMP effort to the tanks that genuinely need it. Only clinical and quarantine tanks carry full IQ/OQ/PQ, temperature mapping and GMP documentation; the research inventory is monitored, maintained and documented, but run lean.
A worked example: a university hospital operates eight cryogenic tanks, two of which hold clinical material. Mixed, all eight potentially fall into GMP scope. Segregated, only two do — with correspondingly less qualification, calibration and change control.
Segregation does carry a cost, and it belongs in the plan. Two smaller tanks evaporate more nitrogen than one large one. Taking datasheet figures as an example: a BSF220+ (238 l) has a static evaporation rate of 4.8 l per day, a BSF420+ (464 l) 8.3 l per day. Two BSF220+ tanks instead of one BSF420+ add roughly 1.3 l of LN₂ per day for a comparable volume — usually a minor item next to running a mixed inventory entirely under GMP.
Equally candid: a research-only lab does not need GMP infrastructure. Monitored tanks, disciplined inventory management and, for biobanks, alignment with ISO 20387 are sufficient.
Consarctic GmbH supplies the complete chain for segregated biospecimen storage from a single source, serving customers in more than 30 countries: from room planning through dedicated tanks for each status to qualification and ongoing service.
Through Design & Build, Consarctic GmbH plans the room layout: which inventories need their own rooms and where tanks can share space. The GMP Validation Suite covers IQ/OQ/PQ and temperature mapping of clinical tanks by certified technicians. Lifecycle & Compliance Care provides maintenance and 24/7 emergency service, 365 days a year.
Consarctic GmbH is certified to EN ISO 13485:2016 and ISO 9001:2015, and its systems are manufactured to GMP-compliant standards. Hospitals including Charité Universitätsmedizin Berlin, Uniklinik Köln, Uniklinikum Erlangen, Tirol Kliniken and Hamad Medical Corporation work with Consarctic systems.
No. It reduces the risk considerably because samples are not immersed in liquid nitrogen, but filling, damaged containers and ice deposits remain potential transmission routes. Material with a positive or unknown infectious status belongs in a dedicated tank.
A dedicated quarantine tank is the most robust solution, because quarantined material has not yet been fully tested. Some GMP frameworks accept quarantine status managed through a validated electronic system; that resolves the status question, but not the contamination risk.
The most robust set-up uses dedicated tanks per status: Consarctic® BSD+ tanks (up to 100,000 cryovials) and BSF+ bag tanks for clinical and quarantine inventories, with ABV+ or ABS+ containers for the leaner research inventory. The Consarctic® Monitoring System with Biolog® records temperature, event and fill data per container, while IQ/OQ/PQ with temperature mapping is applied only to the clinical tanks. Consarctic GmbH also plans the room layout and supports the installation with 24/7 emergency service.
No. Without clinical material, monitored tanks, disciplined inventory management and, for biobanks, alignment with ISO 20387 are sufficient. Once clinical products are added, planning a segregated area early pays off.
Where research and patient care share a roof, storage architecture determines how far GMP reaches and how safe clinical products are. Separate rooms or tanks, one status per vessel and documented transfers keep regulatory effort exactly where it belongs.
Reorganising cryogenic storage at your hospital or institute, or adding a clinical area alongside existing research? Consarctic GmbH plans, supplies, qualifies and supports segregated cryogenic infrastructure for university hospitals and translational centres — one accountable partner from the first room concept to a running, GMP-validated facility. Get in touch.